Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes - PubMed (original) (raw)
Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes
Huei-Ping Tzeng et al. Am J Physiol Heart Circ Physiol. 2008 Mar.
Abstract
High-mobility group box 1 (HMGB1) released from necrotic cells or macrophages functions as a late inflammatory mediator and has been shown to induce cardiovascular collapse during sepsis. Thus far, however, the effect(s) of HMGB1 in the heart are not known. We determined the effects of HMGB1 on isolated feline cardiac myocytes by measuring sarcomere shortening in contracting cardiac myocytes, intracellular Ca2+ transients by using fluo-3, and L-type calcium currents by using whole cell perforate configuration of the patch-clamp technique. Treatment of isolated myocytes with HMGB1 (100 ng/ml) resulted in a 70% decrease in sarcomere shortening and a 50% decrease in the height of the peak Ca2+ transient within 5 min (P < 0.01). The immediate negative inotropic effects of HMGB1 on cell contractility and calcium homeostasis were partially reversible upon washout of HMGB1. A significant inhibition of the inward l-type calcium currents was also documented by the patch-clamp technique. HMGB1 induced the PKC-epsilon translocation, and a PKC inhibitor significantly attenuated the negative inotropic effects of HMGB1. These studies show for the first time that HMGB1 impairs sarcomere shortening by decreasing calcium availability in cardiac myocytes through modulating membrane calcium influx and suggest that HMGB1 maybe acts as a novel myocardial depressant factor during cardiac injury.
Conflict of interest statement
Conflict of Interest
The authors have no conflicts to disclose.
Figures
Figure 1. Effects of HMGB1 on cardiac myocyte contractility and intracellular calcium transients
Recordings of myocyte contractility during the entire period of experimentation in individual cells treated with diluent (A) or HMGB1 (100 ng/mL; B). Vertical axis shows absolute sarcomere length in microns or fluorescence brightness (in arbitrary units). The horizontal axis represents time (in seconds). Representative pacing events recorded under baseline (C) and post treatment with HMGB1 (100 ng/mL; D). Vertical axis represents fluorescence brightness in arbitrary units.
Figure 2. Effects of HMGB1 on cardiac myocyte contractility and peak amplitude of calcium transients
(A) Effect of 100 ng/ml HMGB1 on the sarcomere shortening. (B) Effect of 100 ng/ml HMGB1 on the peak fluorescence brightness. (* p < 0.01 vs. baseline, N = 9 cells from 4 hearts).
Figure 3. Dose-dependent effects of HMGB1 on myocyte contractility and intracellular calcium transients
(A) Effects of increasing concentrations of HMGB1 on sarcomere shortening. (B) Effects of increasing concentrations of HMGB1 on the peak amplitude of calcium transients. (*p < 0.01 vs. diluent; N = 8 cells/condition).
Figure 4. Effect of HMGB1 on L-type calcium currents
(A) Inward L-type calcium currents recorded under baseline conditions, after HMGB1 treatment, and washout. (B) Relative effects of HMGB1 (10 ng/ml) on the L-type calcium currents in isolated myocytes. (C) Time course of the L-type calcium currents in the presence and after washout of HMGB1. (N = 8 cells/condition).
Figure 5. HMGB1 induces PKC-ε translocation in cardiac myoctyes
(A) Representative western blots for cytosolic and membrane PKC-ε. HMGB1 (100 ng/ml: R&D Systems) induced PKC-ε translocation from the cytosol to the membrane fraction. (B) Time course of PKCε translocation in cardiac myocytes after exposure to HMGB1 (100 ng/ml). (*p < 0.01 vs Time 0; n = 4 isolations) (C) Ro-31-8220 (Ro) significantly attenuated the effects of HMGB1 (100 ng/mL; R&D Systems) in a dose dependent manner compared to Diluent (Dil). N= 10–15 cells/condition. (*p < 0.01 vs. Diluent; ‡ p < 0.05 vs. HMGB1 alone). N= 10–15 cells/condition
Figure 6. Effects of anti-RAGE and TLR4 antibodies on HMGB1-induced negative inotropic effects in cardiac myocytes
Cells were pre-incubated (30 min) with each antibody prior to exposure to HMGB1 (100 ng/mL). (A) RAGE blockade improved sarcomere shortening by 32% (B) TLR4 blockade improved sarcomere shortening by 22% (*p < 0.01 vs. Diluent; ‡ p < 0.05 vs. HMGB1 alone). N= 10-15 cells/condition
Similar articles
- Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms.
Schillinger W, Teucher N, Sossalla S, Kettlewell S, Werner C, Raddatz D, Elgner A, Tenderich G, Pieske B, Ramadori G, Schöndube FA, Kögler H, Kockskämper J, Maier LS, Schwörer H, Smith GL, Hasenfuss G. Schillinger W, et al. Circulation. 2007 Jul 3;116(1):57-66. doi: 10.1161/CIRCULATIONAHA.106.666008. Epub 2007 Jun 18. Circulation. 2007. PMID: 17576869 - Targeted gene silencing of tumor necrosis factor attenuates the negative inotropic effects of lipopolysaccharide in isolated contracting cardiac myocytes.
Ramabadran RS, Chancey A, Vallejo JG, Barger PM, Sivasubramanian N, Mann DL. Ramabadran RS, et al. Tex Heart Inst J. 2008;35(1):16-21. Tex Heart Inst J. 2008. PMID: 18427645 Free PMC article. - Pharmacological effects of ATI22-107 [2-(2-{2-[2-chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-acetylamino}-ethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester)], a novel dual pharmacophore, on myocyte calcium cycling and contractility.
Jung AS, Quaile MP, Mills GD, Bednarik DP, Houser SR, Margulies KB. Jung AS, et al. J Pharmacol Exp Ther. 2005 Feb;312(2):517-24. doi: 10.1124/jpet.104.075895. Epub 2004 Nov 18. J Pharmacol Exp Ther. 2005. PMID: 15550574 - Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors.
Su Z, Preusser L, Diaz G, Green J, Liu X, Polakowski J, Dart M, Yao B, Meyer M, Limberis JT, Martin RL, Cox BF, Gintant GA. Su Z, et al. Curr Drug Saf. 2011 Nov 1;6(5):277-84. doi: 10.2174/157488611798918728. Curr Drug Saf. 2011. PMID: 22424534 - Multimodal SHG-2PF Imaging of Microdomain Ca2+-Contraction Coupling in Live Cardiac Myocytes.
Awasthi S, Izu LT, Mao Z, Jian Z, Landas T, Lerner A, Shimkunas R, Woldeyesus R, Bossuyt J, Wood BM, Chen YJ, Matthews DL, Lieu DK, Chiamvimonvat N, Lam KS, Chen-Izu Y, Chan JW. Awasthi S, et al. Circ Res. 2016 Jan 22;118(2):e19-28. doi: 10.1161/CIRCRESAHA.115.307919. Epub 2015 Dec 7. Circ Res. 2016. PMID: 26643875 Free PMC article. Review.
Cited by
- Exercise Training: The Holistic Approach in Cardiovascular Prevention.
Giallauria F, Strisciuglio T, Cuomo G, Di Lorenzo A, D'Angelo A, Volpicelli M, Izzo R, Manzi MV, Barbato E, Morisco C. Giallauria F, et al. High Blood Press Cardiovasc Prev. 2021 Nov;28(6):561-577. doi: 10.1007/s40292-021-00482-6. Epub 2021 Nov 1. High Blood Press Cardiovasc Prev. 2021. PMID: 34724167 Free PMC article. Review. - Comprehensive Mechanism, Novel Markers and Multidisciplinary Treatment of Severe Acute Pancreatitis-Associated Cardiac Injury - A Narrative Review.
Luo Y, Li Z, Ge P, Guo H, Li L, Zhang G, Xu C, Chen H. Luo Y, et al. J Inflamm Res. 2021 Jul 12;14:3145-3169. doi: 10.2147/JIR.S310990. eCollection 2021. J Inflamm Res. 2021. PMID: 34285540 Free PMC article. Review. - Can the calcium-regulating hormones counteract the detrimental impact of pro-inflammatory damage-associated molecular patterns in the development of heart failure?
Adamyan SH, Harutyunyan KR, Abrahamyan HT, Khudaverdyan DN, Mkrtchian S, Ter-Markosyan AS. Adamyan SH, et al. J Investig Med. 2021 Aug;69(6):1148-1152. doi: 10.1136/jim-2020-001754. Epub 2021 May 5. J Investig Med. 2021. PMID: 33952612 Free PMC article. Review. - Reappraising the role of inflammation in heart failure.
Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Adamo L, et al. Nat Rev Cardiol. 2020 May;17(5):269-285. doi: 10.1038/s41569-019-0315-x. Epub 2020 Jan 22. Nat Rev Cardiol. 2020. PMID: 31969688 Review.
References
- Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, Harken AH. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med. 1999;27:1309–1318. - PubMed
- Gibot S, Massin F, Cravoisy A, Barraud D, Nace L, Levy B, Bollaert PE. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med. 2007;33:1347–1353. - PubMed
- Hu K, Mochly-Rosen D, Boutjdir M. Evidence for functional role of epsilonPKC isozyme in the regulation of cardiac Ca(2+) channels. Am J Physiol Heart Circ Physiol. 2000;279:H2658–H2664. - PubMed
- Kim JY, Park JS, Strassheim D, Douglas I, Diaz d V, Asehnoune K, Mitra S, Kwak SH, Yamada S, Maruyama I, Ishizaka A, Abraham E. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol. 2005;288:L958–L965. - PubMed
- Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol. 2005;61:1–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL088243/HL/NHLBI NIH HHS/United States
- GM-62474/GM/NIGMS NIH HHS/United States
- R01 GM062474/GM/NIGMS NIH HHS/United States
- HL-073017/HL/NHLBI NIH HHS/United States
- HL-42250/HL/NHLBI NIH HHS/United States
- R01 HL042250/HL/NHLBI NIH HHS/United States
- R01 HL058081/HL/NHLBI NIH HHS/United States
- R01 HL073017/HL/NHLBI NIH HHS/United States
- HL-58081/HL/NHLBI NIH HHS/United States
- P50 HL054313/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous